Mirum Pharmaceuticals (MIRM)

Executive Summary

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in rare cholestatic liver diseases. Its lead product, LIVMARLI (maralixibat), is approved in the U.S. for Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), generating growing revenue. The company is expanding its pipeline with maralixibat in biliary atresia (Phase 2 completed) and intrahepatic cholestasis of pregnancy (Phase 2 recruiting), as well as earlier-stage programs. Mirum's strategy focuses on leveraging its expertise in bile acid transport inhibition to address high unmet needs in hepatology. With a commercial footprint and advancing pipeline, Mirum is positioned for sustained growth, though it faces competition and regulatory risks typical of rare disease biotechs.

Upcoming Catalysts (preview)

• H2 2027Phase 2 Maralixibat Data in Intrahepatic Cholestasis of Pregnancy (ICP)40% success
• Q4 2026sNDA Filing for Maralixibat in PFIC Based on Phase 3 Long-Term Data70% success
• Q2 2027Initiation of Phase 3 Trial for Maralixibat in Biliary Atresia60% success